XL147: Updated Phase I data

Updated data from 75 patients in an ongoing, open-label, dose-escalation Phase I trial showed that 225 mg oral XL147 daily for 21 days in 28-day cycles produced 1 partial response with a 33% reduction in the target lesion in a patient with non-small cell lung cancer (NSCLC). Patients received 30, 60, 120, 225, 400, 600 or 900 mg oral XL147 daily for 21 days in 28-day cycles or continuous daily dosing at 100, 400 or 600 mg. The MTD for the capsule formulation of XL147 was 600 mg for both dosing schedules. The MTD for the tablet formulation of the compound has not been reached. Dose-limiting toxicities were skin rash and hypersensitivity. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...